## Drug Summary
Tipranavir is a non-peptidic protease inhibitor (PI) used specifically in the treatment of HIV-1 infection. It is categorically used for HIV-1-infected adult patients who show evidence of viral replication and are either highly treatment-experienced or harbor HIV-1 strains resistant to multiple other protease inhibitors. Tipranavir functions by inhibiting the HIV protease, an enzyme crucial for the viral replication process. It is usually co-administered with ritonavir, another protease inhibitor, to enhance its pharmacokinetic profile by inhibiting its metabolism and increasing its plasma concentration. The drug is metabolized predominantly by the cytochrome P450 system in the liver, specifically via CYP3A4. Its absorption is somewhat limited, and detailed quantification data on absorption is not readily available. 

## Drug Targets, Enzymes, Transporters, and Carriers
The primary action of Tipranavir is targeted against the protease enzyme of the HIV-1 virus, referred to as the "pol" gene or HIV-1 protease. This interaction inhibits the cleavage of viral polyproteins essential for forming infectious viral particles. Metabolism of Tipranavir primarily involves the cytochrome P450 enzyme CYP3A4, with additional involvement from CYP2C19, CYP2D6, and UGT1A1. Regarding transporters, Tipranavir interacts with several, including ABCB1 (P-glycoprotein 1), which plays a role in drug expulsion from cells, and various solute carrier family members such as SLCO1B1, SLCO1B3, SLCO2B1, and ABCB11, which influence the drug's distribution and elimination.

## Pharmacogenetics
Tipranavir's pharmacogenetics revolves significantly around its metabolism and interaction with transporters affecting its efficacy and safety profile. Variability in enzymes such as CYP3A4, CYP2C19, and CYP2D6 can influence the drug's plasma levels and overall therapeutic effect. For instance, genetic variants that result in poor metabolizer phenotypes of CYP3A4 might lead to higher drug exposure, increasing the risk of adverse effects, whereas extensive metabolizers might have reduced efficacy. Additionally, genetic variations in ABCB1 (which encodes P-glycoprotein) could modify the drug's distribution across cellular barriers, impacting both efficacy and toxicity. While specific pharmacogenetic guidelines for Tipranavir are not extensively detailed, these genetic factors are critical in guiding personalized therapy in HIV treatment, particularly in managing patients with resistance or intolerance to other therapies.